Association of hepatitis C viral infection with incidence and progression of chronic kidney disease in a large cohort of US veterans

Miklos Z. Molnar, Hazem M. Alhourani, Barry M. Wall, Jun L. Lu, Elani Streja, Kamyar Kalantar‐Zadeh, Csaba P. Kovesdy – 20 December 2014 – An estimated 4 million Americans have been exposed to the hepatitis C virus (HCV). The risks of incident and progressive chronic kidney disease and of mortality in patients with normal kidney function infected with HCV are unclear.

Magnetic resonance imaging and liver histology as biomarkers of hepatic steatosis in children with nonalcoholic fatty liver disease

Jeffrey B. Schwimmer, Michael S. Middleton, Cynthia Behling, Kimberly P. Newton, Hannah I. Awai, Melissa N. Paiz, Jessica Lam, Jonathan C. Hooker, Gavin Hamilton, John Fontanesi, Claude B. Sirlin – 20 December 2014 – Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in children. In order to advance the field of NAFLD, noninvasive imaging methods for measuring liver fat are needed. Advanced magnetic resonance imaging (MRI) has shown great promise for the quantitative assessment of hepatic steatosis but has not been validated in children.

Magnetic resonance imaging and liver histology as biomarkers of hepatic steatosis in children with nonalcoholic fatty liver disease

Jeffrey B. Schwimmer, Michael S. Middleton, Cynthia Behling, Kimberly P. Newton, Hannah I. Awai, Melissa N. Paiz, Jessica Lam, Jonathan C. Hooker, Gavin Hamilton, John Fontanesi, Claude B. Sirlin – 20 December 2014 – Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in children. In order to advance the field of NAFLD, noninvasive imaging methods for measuring liver fat are needed. Advanced magnetic resonance imaging (MRI) has shown great promise for the quantitative assessment of hepatic steatosis but has not been validated in children.

Association of hepatitis C viral infection with incidence and progression of chronic kidney disease in a large cohort of US veterans

Miklos Z. Molnar, Hazem M. Alhourani, Barry M. Wall, Jun L. Lu, Elani Streja, Kamyar Kalantar‐Zadeh, Csaba P. Kovesdy – 20 December 2014 – An estimated 4 million Americans have been exposed to the hepatitis C virus (HCV). The risks of incident and progressive chronic kidney disease and of mortality in patients with normal kidney function infected with HCV are unclear.

CXCR4 inhibition in tumor microenvironment facilitates anti‐programmed death receptor‐1 immunotherapy in sorafenib‐treated hepatocellular carcinoma in mice

Yunching Chen, Rakesh R. Ramjiawan, Thomas Reiberger, Mei R. Ng, Tai Hato, Yuhui Huang, Hiroki Ochiai, Shuji Kitahara, Elizabeth C. Unan, Tejaswini P. Reddy, Christopher Fan, Peigen Huang, Nabeel Bardeesy, Andrew X. Zhu, Rakesh K. Jain, Dan G. Duda – 20 December 2014 – Sorafenib, a broad tyrosine kinase inhibitor, is the only approved systemic therapy for advanced hepatocellular carcinoma (HCC) but provides limited survival benefits.

The impact of phlebotomy in nonalcoholic fatty liver disease: A prospective, randomized, controlled trial

Leon A. Adams, Darrell H. Crawford, Katherine Stuart, Michael J. House, Timothy G. St. Pierre, Malcolm Webb, Helena L.I. Ching, Jenny Kava, Michael Bynevelt, Gerry C. MacQuillan, George Garas, Oyekoya T. Ayonrinde, Trevor A. Mori, Kevin D. Croft, Xianwa Niu, Gary P. Jeffrey, John K. Olynyk – 18 December 2014 – Iron is implicated in the pathogenesis of liver injury and insulin resistance (IR) and thus phlebotomy has been proposed as a treatment for nonalcoholic fatty liver disease (NAFLD).

The impact of phlebotomy in nonalcoholic fatty liver disease: A prospective, randomized, controlled trial

Leon A. Adams, Darrell H. Crawford, Katherine Stuart, Michael J. House, Timothy G. St. Pierre, Malcolm Webb, Helena L.I. Ching, Jenny Kava, Michael Bynevelt, Gerry C. MacQuillan, George Garas, Oyekoya T. Ayonrinde, Trevor A. Mori, Kevin D. Croft, Xianwa Niu, Gary P. Jeffrey, John K. Olynyk – 18 December 2014 – Iron is implicated in the pathogenesis of liver injury and insulin resistance (IR) and thus phlebotomy has been proposed as a treatment for nonalcoholic fatty liver disease (NAFLD).

Subscribe to